Saurabh Aggarwal
Research Subjects
Saurabh Aggarwal has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Kathleen F. Villa
Jazz Pharmaceuticals, Inc, Palo Alto, CA, USA
2 shared publicationsOzlem Topaloglu
Novel Health Strategies, Bethesda, MD, USA
2 shared publicationsPaul Richardson
Jerome Lipper Multiple Myeloma Center, Division of Hematologic Malignancy, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
2 shared publicationsSelim Corbacioglu
Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, University of Regensburg, Regensburg, Germany
2 shared publicationsCharles Yonan
Neurocrine Biosciences, Inc., San Diego, CA, USA
1 shared publicationStanley N Caroff
Corporal Michael J Crescenz Veterans Affairs Medical Center & the Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
1 shared publication
Latest Publications
- 1 April 2019
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 54 (12) , 2117-2119
Publisher Correction: Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS)
The original version of this article included some minor typesetting errors in Table 1–a corrected version of which is provided in this correction article and has been corrected in the original article–and one error in text, which has been corrected in the original article. Furthermore, the article was erroneously published with the copyright holders as ‘Springer Nature Limited’, however, since the article is Open Access, the copyright holders should in fact be ‘The Author(s)’. This has also been corrected in the original article.
- 1 April 2019
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 54 (12) , 2117-2119
Publisher Correction: Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS)
The original version of this article included some minor typesetting errors in Table 1–a corrected version of which is provided in this correction article and has been corrected in the original article–and one error in text, which has been corrected in the original article. Furthermore, the article was erroneously published with the copyright holders as ‘Springer Nature Limited’, however, since the article is Open Access, the copyright holders should in fact be ‘The Author(s)’. This has also been corrected in the original article.
- Open Access
- 25 February 2019
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 54 (12) , 1951-1962
Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS)
Veno-occlusive disease (VOD), also called sinusoidal obstruction syndrome (SOS), is a potentially life-threatening complication of hematopoietic stem cell transplantation (HSCT) conditioning or high-dose nontransplant chemotherapy. VOD/SOS with multi-organ dysfunction (MOD) is associated with a mortality rate of > 80%. Defibrotide (25 mg/kg/day) is approved to treat hepatic VOD/SOS with renal or pulmonary dysfunction post HSCT in the United States and to treat severe hepatic VOD/SOS in patients > 1 month of age in the European Union. A random effects model was used for pooling data from 17 systematically chosen defibrotide studies. For patients in these reports (n = 2598), and those in the subset of 10 reports of patients treated with ~ 25 mg/kg/day (n = 1691), estimated Day + 100 survival rates were 54% and 56%, respectively. Among those patients treated with ~ 25 mg/kg/day, estimated Day + 100 survival was 44% among patients with MOD and 71% in patients without MOD; survival was 41% and 70%, respectively, for the population of patients receiving any dose of defibrotide. Safety results were not pooled owing to differences in reporting methodology but were generally consistent with the known tolerability profile of defibrotide. This analysis provides the largest assessment of survival in patients treated with defibrotide for VOD/SOS with or without MOD.
- 25 February 2019
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 54 (12) , 1951-1962
Open AccessSystematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS)
Veno-occlusive disease (VOD), also called sinusoidal obstruction syndrome (SOS), is a potentially life-threatening complication of hematopoietic stem cell transplantation (HSCT) conditioning or high-dose nontransplant chemotherapy. VOD/SOS with multi-organ dysfunction (MOD) is associated with a mortality rate of > 80%. Defibrotide (25 mg/kg/day) is approved to treat hepatic VOD/SOS with renal or pulmonary dysfunction post HSCT in the United States and to treat severe hepatic VOD/SOS in patients > 1 month of age in the European Union. A random effects model was used for pooling data from 17 systematically chosen defibrotide studies. For patients in these reports (n = 2598), and those in the subset of 10 reports of patients treated with ~ 25 mg/kg/day (n = 1691), estimated Day + 100 survival rates were 54% and 56%, respectively. Among those patients treated with ~ 25 mg/kg/day, estimated Day + 100 survival was 44% among patients with MOD and 71% in patients without MOD; survival was 41% and 70%, respectively, for the population of patients receiving any dose of defibrotide. Safety results were not pooled owing to differences in reporting methodology but were generally consistent with the known tolerability profile of defibrotide. This analysis provides the largest assessment of survival in patients treated with defibrotide for VOD/SOS with or without MOD.
- Open Access
- 1 February 2018
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 7 (2) , 135-148
Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review
Up to 30% of patients taking antipsychotics may develop tardive dyskinesia (TD). Recent evidence-based recommendations demonstrate an unmet need for effective TD management. This systematic review was designed to update the evidence for TD treatment, comparing two vesicular monoamine transporter 2 (VMAT2) inhibitors, tetrabenazine and valbenazine. Of 487 PubMed/Embase search results, 11 studies met the review criteria. Valbenazine efficacy was demonstrated in rigorously designed clinical trials that meet the guidelines for AAN Class I evidence. Due to differences in study designs and a lack of standardized and controlled trials with tetrabenazine, a formal meta-analysis comparing the agents was not possible. However, valbenazine appears to have fewer side effects and a more favorable once-daily dosing regimen for the treatment of TD.
- 1 February 2018
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 7 (2) , 135-148
Open AccessTreatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review
Up to 30% of patients taking antipsychotics may develop tardive dyskinesia (TD). Recent evidence-based recommendations demonstrate an unmet need for effective TD management. This systematic review was designed to update the evidence for TD treatment, comparing two vesicular monoamine transporter 2 (VMAT2) inhibitors, tetrabenazine and valbenazine. Of 487 PubMed/Embase search results, 11 studies met the review criteria. Valbenazine efficacy was demonstrated in rigorously designed clinical trials that meet the guidelines for AAN Class I evidence. Due to differences in study designs and a lack of standardized and controlled trials with tetrabenazine, a formal meta-analysis comparing the agents was not possible. However, valbenazine appears to have fewer side effects and a more favorable once-daily dosing regimen for the treatment of TD.
- 8 April 2014
- Published by Springer Nature in Nature Biotechnology
- Vol. 32 (4) , 323-330
A survey of breakthrough therapy designations
- 8 April 2014
- Published by Springer Nature in Nature Biotechnology
- Vol. 32 (4) , 323-330
A survey of breakthrough therapy designations
- 7 December 2012
- Published by Springer Nature in Nature Biotechnology
- Vol. 30 (12) , 1191-1197
What's fueling the biotech engine—2011 to 2012
- 7 December 2012
- Published by Springer Nature in Nature Biotechnology
- Vol. 30 (12) , 1191-1197
What's fueling the biotech engine—2011 to 2012